The effect of drugs acting on CCK receptors and rat free exploration in the exploration box

Journal of Physiology and Pharmacology

Volumn 48, Issue 2, 1997, Pages 239-251

  Matto, V ^a   Harro, J ^a   Allikmets, L ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

Anxiety; Cholecystokinin; Citalopram; Desipramine; Exploration box; Exploratory behaviour; Rat

Indexed keywords

CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CITALOPRAM; DESIPRAMINE; DEVAZEPIDE; TETRAGASTRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR MODIFICATION; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROTRANSMISSION; NONHUMAN; REARING; RECEPTOR BLOCKING; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANXIETY; BENZODIAZEPINONES; CITALOPRAM; DESIPRAMINE; DEVAZEPIDE; EXPLORATORY BEHAVIOR; FEMALE; HORMONE ANTAGONISTS; PHENYLUREA COMPOUNDS; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ; SEROTONIN UPTAKE INHIBITORS;

EID: 0030802127     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Lindefors N, Lindén A, Brené S, Sedvall G, Persson H. CCK peptides and mRNA in the human brain. Prog Neurobiology 1993; 40: 671-690.
2. Bradwejn J, Koszycki D, Shriqui Ch. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorders. Clinical and behavioral findings. Arch Gen Psychiatry 1991; 48: 603-610.
3. Harro J, Vasar E. Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour? Neurosci Biobehav Rev 1991; 15: 473-477.
4. Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol Sci 1993; 14: 244-249.
5. Moran TH, Robinson PH, Goldrich MS, McHugh PH. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986; 362: 175-179.
6. Beinfeld MC. Cholecystokinin/gastrin. In Psychopharmacology. The Fourth Generation of Progress FE Bloom, DJ Kupfer (eds). N. Y. Raven Press, Ltd., 1995; pp. 585-594.
7. Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 1991; 88: 1130-1133.
8. Koszycki D, Cox BJ, Bradwejn J. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry 1993: 150: 1881-1883.
9. Pavlasevic S, Bednar I, Quereshi GA, Södersten P. Brain cholecystkinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport 1993; 5: 225-228.
10. B receptors in behavioural and hormonal studied in rats. Naunyn-Schmiedebergs Arch Pharmacol 1994; 349: 478-484.
11. B receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 1991; 193: 379-381.
12. Rex A, Fink H, Marsden CA. Effects of BOC-CCK-4 and L 365260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus-maze. Neuropharmacology 1994; 33: 559-565.
13. Bradwejn J, Koszycki D, Burin M. Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatr Neurosci 1991; 16: 91-95.
14. Hughes J, Boden P, Costall B et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990; 87: 6728-6732.
15. Bickerdike MJ, Marsden CA, Dourish CT, Fletcher A. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur J Pharmacol 1994; 271: 403-411.
16. Bock MG, DiPardo RM, Evans BE et al. Development of 1,4-benzodiazepine cholecystokinin type B antagonists. J Med Chem 1993; 36: 4276-4292.
17. Tyrer P, Tyrer J. Antidepressive drugs for treatment of anxiety disorders - and vice versa. In Handbook of depression and anxiety. A biological approach. JA den Boer, JM Ad Sitsen (eds). N. Y. Marcel Decker, Inc., 1994; pp. 497-514.
18. Schweizer E, Rickels K, Uhlenhuth EH. Issues in the long term treatment of anxiety disorders. In Psychopharmacology. The Fourth Generation of Progress. FE Bloom, DJ Kupfer (eds). N. Y. Raven Press, Ltd., 1995; pp. 1349-1360.
19. McElroy SL, Keck PE, Friedman LM. Minimizing and managing antidepressant side effects. J Clin Psychiatry 1995; 56 (Suppl 2): 49-55.
20. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 52 (Suppl 6): 12-21.
21. Chopin P, Briley M. Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol Sci 1987; 8: 383-388.
22. Griebel G, Moreau J-L, Misslin R, Martin JR. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 1994; 113: 463-470.
23. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ. Different modulation of antipredator defensive behaviour in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 1995; 120: 57-66.
24. Harro J. Measurement of exploratory behaviour in rodents. In Methods in Neurosciences, RA Conn (ed). Volume 14. San Diego Academic Press, Inc., 1993; pp. 359-377.
25. Lister RG. Ethologically-based animal models of anxiety disorders. Pharmac Ther 1990; 46: 321-340.
26. Blanchard JR, Yudko EB, Rodgers RJ, Blanchard DC. Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behav Brain Res 1993; 58: 155-165.
27. Treit D. Animal models of anxiety and anxiolytic drug action. In Handbook of depression and anxiety. A biological approach. JA den Boer, JM N. Y. Marcel Dekker, Inc., 1994; pp. 201-224.
28. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 1986; 24: 525-529.
29. Handley SL, McBlane JW. An assessment of the elevated X-maze for studing anxiety and anxiety-modulating drugs. J Pharmac Toxic Meth 1993; 29: 129-138.
30. Rodgers RJ, Cole JC. The elevated plus-maze: pharmacology, methodology, and ethology. In Ethology and Psychopharmacology. SJ Cooper, CA Hendrie (eds). N. Y. Wiley Press, Inc., 1994; pp. 9-44.
31. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology 1994; 116: 56-64.
32. Walsh RN, Cummins RA. The open field test: a critical review. Psychol Bull 1976; 83: 482-504.
33. Kelley AE, Cador M, Stinus L. Exploration and its measurement. In Neuromethods 13: Psychopharmacology. AA Boulton, GL Baker, AJ Greenshow (eds). Clifton, N. J. The Humana Press, Inc., 1989; pp. 95-144.
34. Harro J, Oreland L, Vasar E, Bradwejn J. Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Eur Neuropsychopharmacol 1995; 5: 447-455.
35. Otter MH, Sõukand R, Oreland L, Harro J. Pharmacological validation of the exploration box: preliminary studies. Pharmacol Toxicol 1995; 76 (Suppl 3): 60.
36. Otter M, Skrebuhhova T, Matto V, Harro J. Studies on validation of a method to measure exploratory behaviour in rat. In Welfare and science. Proceedings of the sixth symposium of the Federation of European Laboratory Animal Science Association. PN O'Donoghue (ed). London, U. K. Royal Society of Medicine Press, 1997, in press.
37. Matto V, Allikmets L, Harro J. The mechanism of anxiogenic-like effect of antidepressants on exploratory behaviour in rats. Pharmacol Toxicol 1995; 76 (Suppl 3): 53.
38. Kaesermann HP. Stretched attend posture, a non-social form of ambivalence, is sensitive to a conflict-reducing drug action. Psychopharmacology 1986; 89: 31-37.
39. Kaesermann HP, Dixon AK. Further validation of the SAP test, a simple behavioural conflict test in mice. Psychopharmacology 1986; 89: S19.
40. Matto V, Harro J, Allikmets L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology 1997; in press.
41. Rex A, Barth T, Voigt J-P, Domeney AM, Fink H. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neurosci Lett 1994; 172: 139-142.
42. Johnston AL, File SE. Sex differences in animal tests of anxiety. Physiol Behav 1990; 49: 245-250.
43. Rex A, Sondern U, Voigt JP, Franck S, Fink H. Strain differences in fear-motivated behavior of rats. Pharmacol Biochem Behav 1996; 54: 107-111.
44. B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology 1995; 121: 109-117.
45. B antagonist, in panic disorder. Biol Psychiatry 1995; 37: 462-466.
46. Charrier D, Dangoumau L, Puech AJ, Hamon M, Thiébot M-H. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology 1995; 121: 127-134.
47. B) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology 1996; 124: 355-364.
48. Hökfelt T. Neuropeptides in perspective: the last ten years. Neuron 1991; 7: 867-879.